Baird commenting Genzyme (NASDAQ:GENZ), saying that they understand from GENZ that CMS has reversed its prior negative decision (announced in October) to cut Synvisc reimbursement by grouping all viscosupplementation products into one J-code in 2007.
A quick look at the CMS website confirms this positive development. Synvisc reimbursement will be $198/dose (three doses required per course), comparable to the 2006 level.
Orthovisc - Synvisc's closest comp in the category - is reimbursed at $200.54/dose, making the economics fairly comparable across the board.
As things stand today, Synvisc will no longer be unprofitable for physicians to administer, eliminating the need for a dramatic price decrease.
Based on this development, firm is raising their Synvisc revenue estimates to $266M from $229M, resulting in a new 2007 EPS estimate of $3.17.
Notablecalls: The negative reimpursement decision came out 30/10, initially sending the stock down 2 points. Simple logic makes me to expect the same upside today.